Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to shield transplant patients from deadly fungal infections

NCT ID NCT06541067

Recruiting now Disease control Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether the antifungal drug posaconazole can prevent serious fungal infections in 30 adults with blood cancer who are receiving a stem cell transplant from a donor. These patients are at high risk because of newer transplant methods. The study will check if enough of the drug stays in the blood to be effective, with close monitoring during the first weeks after transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
posaconazole
What this could lead to
If successful, this could show that posaconazole effectively prevents dangerous fungal infections in high-risk transplant patients, leading to better infection control guidelines.
What could go wrong
This is a small, early-phase study with only 30 participants, so results may not apply to all patients. Posaconazole can be under-dosed, and side effects or drug interactions are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm systemic mycosis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGIC MALIGNANCY

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU Nantes

    RECRUITING

    Nantes, France, 44000, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.